ZNF614 Inhibitors
Chemical inhibitors of ZNF614 utilize multiple approaches to dampen its function by interfering with various signaling pathways and cellular processes that are essential for its activity. LY294002 and Wortmannin, for example, target phosphatidylinositol 3-kinase (PI3K), which is crucial for the activation of AKT. AKT phosphorylation is a critical event for the activation of several transcription factors, which can regulate the function of ZNF614. By inhibiting PI3K, these chemicals lead to a decrease in AKT phosphorylation, thereby reducing the transcriptional activity that ZNF614 might influence. Similarly, PD98059 and U0126 act as inhibitors of MEK, which is upstream of ERK signaling. The ERK pathway is known to play a significant role in the regulation of DNA-binding protein functions, and its inhibition can result in a compromised ability of ZNF614 to effectively bind its DNA targets.
Additionally, SB203580 and SP600125 inhibit p38 MAPK and JNK, respectively, which are kinases that modulate the activity of transcription factors. The inhibition of these kinases can lead to altered transcription factor activities, potentially inhibiting the functional role of ZNF614 in gene expression. ROCK inhibitor Y-27632 impacts the cytoskeletal dynamics that are crucial for the nuclear localization and DNA-binding ability of ZNF614, while PP2 disrupts Src family kinases, which can affect various signaling cascades involved in transcriptional regulation. Bortezomib's proteasome inhibition can lead to an accumulation of proteins that may otherwise regulate the stability and turnover of ZNF614, thereby inhibiting its function. Sorafenib, as a kinase inhibitor, disrupts multiple receptor tyrosine kinase signaling pathways, which may be essential for the regulation of ZNF614 activity. Lastly, Thapsigargin disrupts calcium homeostasis by inhibiting SERCA, which can lead to a cascade of events resulting in the inhibition of calcium-dependent signaling pathways, potentially essential for the activity of ZNF614.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which is involved in AKT signaling. Inhibition of PI3K activity can decrease AKT phosphorylation and activity, leading to reduced transcription factor activity and possibly reducing ZNF614 influence on gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is upstream of the ERK pathway. ERK is often involved in the regulation of DNA-binding proteins; inhibiting ERK activation may reduce ZNF614's ability to interact with its target DNA sequences effectively. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, the chemical can decrease the activation of transcription factors that may be necessary for the full activation of ZNF614, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can be involved in the regulation of a variety of transcription factors. Inhibition of JNK could disrupt signaling pathways that assist in the functional activity of ZNF614. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits ROCK, which can affect cytoskeletal organization. This inhibitor may impair the nuclear localization or DNA-binding ability of ZNF614 by altering the cytoskeletal dynamics that ZNF614 might depend on for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, preventing the activation of ERK1/2. This could inhibit the phosphorylation and activation of transcription factors that regulate the function of ZNF614, thereby inhibiting ZNF614 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases can be involved in multiple signaling pathways that regulate transcription factors. By inhibiting Src kinases, PP2 could reduce the phosphorylation and activity of proteins that regulate the functional activity of ZNF614. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, similar to LY294002. It prevents the formation of PIP3, which is essential for AKT activation. Reduced AKT activity can lead to a decrease in transcription factor activity that may be necessary for ZNF614 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in protein synthesis and cell growth. By inhibiting mTOR, this compound might reduce the synthesis of proteins that interact with or regulate ZNF614, thus inhibiting its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, which may lead to an accumulation of misfolded or ubiquitinated proteins. This can interfere with the protein turnover required for the proper functioning of ZNF614. | ||||||